Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892931 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
A Phase 2 study of Glioblastoma Multiforme, sponsored by Myrexis.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 10
- Study locations
NCT00892931: Completed Phase 2 study of Glioblastoma Multiforme, sponsored by Myrexis.
NCT00892931 is a Phase 2 study of Glioblastoma Multiforme that has completed, run by Myrexis. The registered enrollment target is 56 participants, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (42% lower). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00892931, a Phase 2 study of Glioblastoma Multiforme, has completed, sponsored by Myrexis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme
Conditions Studied
Interventions
- DRUG Azixa
Study Locations (10)
Massachusetts
- Tufts Medical Center - Boston
- Lahey Clinic - Burlington
- University of Massachusettes - Worcester
California
- Cedars-Sinai Medical Center - Los Angeles
- Stanford University - Stanford
Arizona
- Barrow Neurological Institute - Phoenix
Illinois
- Northwestern University - Chicago
New Hampshire
- Darthmouth -Hitchcock Medical Center - Lebanon
New York
- Columbia University - New York
Washington
- SCCA/University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-04 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
What the finished NCT00892931 record still lists
NCT00892931 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 96-participant average among 88 other Glioblastoma Multiforme trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention - of which Azixa is the first listed.
NCT00892931 lists 10 locations in 7 states (Massachusetts, California, Arizona).
Frequently Asked Questions
What is clinical trial NCT00892931 about?
NCT00892931 is a clinical study titled "Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme". The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme
What is the current status of trial NCT00892931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2009-04. Estimated completion is 2011-09.
What conditions does trial NCT00892931 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme.
What interventions are being tested in trial NCT00892931?
The interventions under investigation include: Azixa (DRUG).
Who is sponsoring clinical trial NCT00892931?
This trial is sponsored by Myrexis, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00892931 being conducted?
This trial has 10 study locations across Arizona, California, Illinois, Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma Multiforme
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00892931's enrollment target sits among peer trials
56 33rd of 88 higher than 56 of 88 other Glioblastoma Multiforme trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma Multiforme trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
RECRUITING · Phase 2
-
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia